Myoclonus is a symptom rather than a disease. It is described as involuntary jerking of a muscle. It is caused by sudden muscle contractions known as positive myoclonus. Myoclonus caused by muscle relaxation is called negative myoclonus. Myoclonic jerks could occur in sequence, alone and in a pattern, or without pattern. Myoclonus can be classified into action myoclonus, cortical reflex myoclonus, palatal myoclonus, essential myoclonus, reticular reflex myoclonus, progressive myoclonus epilepsy (PME), sleep myoclonus, and stimulus-sensitive myoclonus. Action myoclonus is muscular jerking triggered or intensified by voluntary movement.
Myoclonus can be caused by underlying conditions such as shakes or spasms due to anxiety or exercise, infant muscle twitching during sleep or after feeding, lipid storage disease, chemical or drug poisoning, autoimmune inflammatory conditions, Parkinson's disease, Lewy body dementia, Alzheimer's disease, multiple system atrophy, Creutzfeldt-Jakob disease, and stroke. People with myoclonus often describe their symptoms and signs as shakes or spasms and jerks that are brief, shock-like, sudden, involuntary, variable in intensity and frequency, and sometimes severe enough to interfere with eating, speaking, or walking. Neurology professionals diagnose myoclonus with the help of these signs and symptoms. They also use electroencephalography (EEG), electromyography (EMG), magnetic resonance imaging (MRI), and laboratory tests such as autoimmune disease, kidney or liver disease, metabolic disorders, and others. Generally, myoclonus is managed by tranquilizers and anticonvulsants. Levetiracetam (Keppra), primidone (Mysoline), and valproic acid (Depakene) are anticonvulsants that reduce myoclonus symptoms. Clonazepam is a more common tranquilizer used for myoclonus. According to PubMed literature review, prevalence of myoclonus was 4 cases per 100,000 in Japan in 2011. Prevalence of the condition increases with age.
Increase in research and development, introduction of novel disease therapies, rise in demand for effective therapies among patients, and surge in disease prevalence are projected to fuel the growth of the global myoclonus drugs market. Rise in prevalence of chronic diseases such as cardiovascular, neurovascular, and arthritis, and increase in health care insurance coverage are the other factors likely to accelerate the growth of the global myoclonus drugs market.
The global myoclonus drugs market can be segmented based on drug type, distribution channel, and region. In terms of drug type, the market can be categorized into tranquilizers, botulinum toxin (Botox), and anticonvulsants. Botulinum toxin can help treat myoclonus where a discrete body part is affected. Based on distribution channel, the global myoclonus drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. In term of revenue, the hospital pharmacies segment dominated the global myoclonus drugs market in 2016.
Geographically, the global myoclonus drugs market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for myoclonus drugs. In terms of revenue, the U.S. holds a major share of the market in North America. The market in Europe is expanding rapidly due to high prevalence of myoclonus in the region. The myoclonus drugs market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the market in Asia Pacific between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and rise in awareness among the people. Brazil and Mexico dominate the market in Latin America. South Africa, Turkey, and other developing countries in Middle East & Africa contribute to the growth of the myoclonus drugs market in MEA.
Key players operating in the myoclonus drugs market include Allergan plc, Pfizer, Inc., GlaxoSmithKline plc, Wockhardt Ltd.., Teva Pharmaceutical Industries Ltd, Novartis AG, Johnson & Johnson, Cephalon, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.